Compounds, compositions and methods for increasing cftr activity
WO2018201126A1
4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
CA3041675A1
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
AU2017348186A1
Pyridazine derivatives, compositions and methods for modulating CFTR
US2019248779A1
Compounds, compositions, and methods for increasing cftr activity
EP3472156A1
Compounds, compositions, and methods for increasing cftr activity
WO2017196843A1
Methods of identifying cftr modulators
BR112018070747A2
silicone atoms containing ivacaftor analogs
US2018369209A1
Methods of treating pulmonary diseases and disorders
BR112018007021A2
cftr modulation compounds, compositions and methods
US2019022071A1
Methods of treating pulmonary diseases and disorders
US2018214419A1
Compounds, compositions, and methods of increasing CFTR activity
CA2971858A1
Compounds, compositions, and methods for increasing cftr activity
CA2971835A1
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US2017369482A1
Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105484A1
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2952862A1
Compounds, compositions and methods of increasing cftr activity
